Skip to content
lifestyle.ebusinessplanet.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Spyre Therapeutics, Inc.
Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 5, 2026
Spyre Therapeutics Announces Grants of Inducement Awards
May 1, 2026
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million
April 16, 2026
Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock
April 14, 2026
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
April 13, 2026
Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
April 13, 2026
Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
March 10, 2026
Spyre Therapeutics Announces Presentations at the 21st ECCO Congress Supporting Differentiated Profile of SPY003 and Novel Animal Studies Demonstrating Superiority of Combination Approach
March 9, 2026
←
Previous Page
1
2